#binance #hype #zec #near
12/11/25 16:32 UTC-04

Biotechnology company Cypherpunk Technologies is actively buying Zcash

Leap Therapeutics, a company whose shares are traded on the Nasdaq exchange, has changed its name to Cypherpunk Technologies Inc. after adopting a new strategy focused on accumulating digital assets. The main focus is on the privacy cryptocurrency Zcash (ZEC).

To achieve this, the Cambridge-based biotech firm announced plans to raise $58.88 million in capital, led by Winklevoss Capital, the venture firm founded by Gemini founders Cameron and Tyler Winklevoss.

The company has already purchased 203,775 ZEC at an average price of $245 per coin, spending $50 million in total. In doing so, it made a strong bet on a cryptocurrency that enables zero-disclosure transaction validation, without revealing wallet addresses or transaction amounts.

Over the past two months, Zcash has risen nearly tenfold, reaching a peak of $735. Subsequently, according to CoinGecko, its price corrected downward to $466 — about 85% below its 2016 all-time high of $3,191.

ZEC price change over 7 days — CoinGecko data

Galaxy Digital analyst Will Owens believes that Zcash is gaining popularity as an alternative to Bitcoin amid growing concerns about on-chain surveillance.

“Supporters of Zcash call it an ‘encrypted Bitcoin,’ a return to the cypherpunk principles that are resonating again in an era of pervasive on-chain tracking,” the expert said.

See also: "Bitcoin price today: steady at $102.5K"

#Zcash #Buy

Editor: Alyona Nabok
Comments

Similar

08/06/26 06:03 UTC-04

ZEC Rises 41.5% After Critical Network Vulnerability

Zcash Open Development Lab (ZODL) founder Josh Swihart reported that a critical vulnerability in the Orchard shielded pool had been fixed. Against this backdrop, the asset’s price began to recover after a major decline.

08/06/26 00:12 UTC-04

Grayscale Warns That Strategy May Struggle to Keep Buying Bitcoin

Strategy’s Bitcoin-buying model has come back under scrutiny after Grayscale warned that current share prices could limit its ability to continue accumulating. The concern emerged amid a Bitcoin sale, pressure from STRC dividends and doubts over whether Strategy can keep financing purchases without stronger investor demand.